LeonaBio, Inc. Financials

LONA

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 7 available years

Income Statement	DEC 2025	DEC 2024	DEC 2023	DEC 2022	DEC 2021
Cost of Revenue	$68	$4	-$2	$10	$0
General & Administrative	$17	$26	$33	$33	$21
Research & Development	$18	$71	$94	$61	$43
Total Operating Expenses	$102	$101	$125	$104	$64
Operating Income	-$102	-$101	-$125	-$104	-$64
Non-Operating
Net Interest Expense	–	–	–	–	-$0
Other Non-Operating Income (Expense)	$1	$4	$8	$3	$0
Income Tax Expense	$0	–	–	–	–
Net Income
Net Income	-$106	-$97	-$118	-$96	-$55
EPS (Basic)	-$24.70	-$25.19	-$30.90	-$25.30	-$14.90
EPS (Diluted)	-$24.70	-$25.19	-$30.90	-$25.30	-$14.90
Weighted Avg Shares (Basic)	4.3M	38.5M	38.0M	37.7M	36.9M
Weighted Avg Shares (Diluted)	4.3M	38.5M	38.0M	37.7M	36.9M
Shares Outstanding	4.3M	3.8M	3.8M	3.8M	3.7M

LeonaBio (LONA) financials: revenue, profit and margins

LeonaBio (LONA) generated about n/a in revenue and -$141 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is LeonaBio profitable?+

LeonaBio reported about -$141 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on LONA: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 4 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with LONA

CompareIntrinsic value

CVMCel-Sci Corporation

$1.38-2.13%0

ARMPArmata Pharmaceuticals Inc.

$3.14+1.62%30

PLURPluri Inc.

$1.23-3.15%30

BCABBioAtla, Inc.

$2.00+0.00%0

STROSutro Biopharma, Inc.

$9.94+4.52%10

RVMDRevolution Medicines Inc.

$199.21+2.56%10

APTOFAptose Biosciences Inc.

No recent price10

ELOXEloxx Pharmaceuticals, Inc.

$12.74-1.39%20

Held by ETFs

LONA is in 1 US ETF. The largest of them, with LONA's weight in each:

Simplify Propel Opportunities ETFSURI1.78%of the fund

Spot a number that looks wrong? Check it in LONA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LONA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.